RESUMEN
Background: Previous studies have reported that statins have inconsistent and marginal cardiovascular (CV) benefits in patients with end-stage renal disease (ESRD). However, whether statins play a secondary preventive role in patients with peripheral artery disease (PAD) and ESRD remains unclear. Objectives: This study aimed to compare the long-term clinical outcomes between statin users and nonusers with PAD and ESRD. Methods: This retrospective cohort study assessed the long-term protective effects of statins using data from the National Health Insurance Research Database in Taiwan. Propensity score matching was performed according to sex, age, index year, related comorbidities, and medications. The main outcomes were limb events and major adverse CV events (MACEs). Results: The statin user group (n = 4,460) was compared with the propensity score-matched statin nonuser group (n = 4,460). The mean age of the matched patients was 64 years, and 40% of the patients were men. The baseline characteristics of the groups were well-balanced. The overall limb event and MACE rates were not different between the two groups. However, the statin user group had lower rates of limb amputation [adjusted hazard ratio (aHR): 0.85, 95% confidence interval (CI): 0.73-0.99], stroke (aHR: 0.71, 95% CI: 0.62-0.83), CV death (aHR: 0.46, 95% CI: 0.32-0.66), and all-cause death (aHR: 0.45, 95% CI: 0.42-0.48) despite having a higher rate of percutaneous transluminal angioplasty for PAD. Conclusions: This population-based retrospective cohort study demonstrated that statin therapy was associated with a lower risk of limb amputation, nonfatal stroke, CV death, and all-cause death in patients with PAD and ESRD.
RESUMEN
Transition metal-based nitrogen-doped carbon (M-Nx -C) is considered as a promising catalyst for the oxygen reduction reaction (ORR) in clean energy storage and conversion devices. Herein, ZnCo dual-atomic sites are incorporated in hierarchical N-doped carbon (HNC), with 1D nanotubes wrapped in 2D nanosheets structure (termed as 1D@2D ZnCo-HNC), via a one-step bio-inspired pyrolysis. The feeding ratio of Zn to Co precursor and pyrolytic temperature are critically modulated to achieve well-defined morphologies of the products, endowing them with the integrated merits of nanotubes and nanosheets as efficient ORR catalysts. Benefiting from the particular structure and electronic regulation of Zn on Co, the ZnCo-Nx dual-atomic system exhibits excellent ORR catalytic characteristics with an onset potential of 1.05 V and a half-wave potential of 0.82 V. Density functional theory calculations further explain the regulating role of Zn, such that the adjusted Co in ZnCo-Nx sites significantly reduces the energy cost to ultimately facilitate the ORR. Moreover, the Zn-air battery assembled with ZnCo-HNC is capable of delivering the maximum power density of 123.7 mW cm-2 and robust stability for 110 h (330 cycles). This method provides a promising strategy for fabricating efficient transition metal-based carbon catalysts for green energy devices.
RESUMEN
Three new isoflavone glucosides, kudonol A-C (1-3), two new ester derivatives of phenylpropanoid, kudolignan A and B (4-5) and five known compounds, (-)-maackiain (6), neoliquiritin (7), methyl 4-coumarate (8), methyl ferulate (9) and (+)-wikstromol (10), were isolated from an extract of dried seeds of the traditional Chinese medicinal plant Sophora alopecuroides L. Their structures were established by NMR and HRESIMS data analyses. The monosaccharide part's configuration of isoflavone glucosides was confirmed by acid hydrolysis and analyzed by a JAsco OR-4090 chiral detector, comparing it to standard substance D-glucose. The cytotoxicity effects against HeLa, Hep3B, MCF-7 and H1299 cells were tested by CCK-8 assay.
Asunto(s)
Semillas/química , Sophora/química , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Humanos , Concentración 50 Inhibidora , Extractos Vegetales/farmacología , Espectroscopía de Protones por Resonancia MagnéticaRESUMEN
To assess the long-term use of L-dopa alone vs L-dopa-sparing therapy, as initial treatment, provides the most efficient long-term control of symptoms and best quality of life for people with early Parkinson's disease (PD). PubMed; Google scholar; Cochrane Central Register of Controlled Trials and the Web of Science were searched for randomised, placebo-controlled trials (RCTs) on L-dopa alone and L-dopa sparing as initial treatment in early PD patients. We used a random effects model rather than a fixed effects model because of this takes into account heterogeneity between multi-studies. Eleven RCTs were included. The results showed that L-dopa alone could evidently improve the UPDRS part I (p = 0.005), part II (p < 0.0001), part III (p < 0.0001) and UPDRS total score (p = 0.004) compared with L-dopa-sparing therapy in PD patients. Meanwhile, a reduced risk of dyskinesia (p < 0.0001, RR = 1.88, 95 % CI 1. 37-2.59) and wearing-off phenomenon (p < 0.00001, RR = 1.36, 95 % CI 1. 20-1.55) in patients treated initially with L-dopa-sparing therapy compared to L-dopa has been consistently reported. What is more, we found more patients on aL-dopa-sparing therapy were more than triple as likely to discontinue treatment prematurely due to adverse events than L-dopa treatment patients (43.7 vs 15.8 %). L-Dopa alone is the most effective medication available for treating the motor symptoms of PD patients, despite the greater incidence of involuntary movements. Meanwhile, more patients on dopamine agonists or MAOBI were more likely to discontinue treatment prematurely than L-dopa alone treatment patients within the long follow-up period.
Asunto(s)
Antiparkinsonianos/uso terapéutico , Levodopa/uso terapéutico , Inhibidores de la Monoaminooxidasa/uso terapéutico , Tratamientos Conservadores del Órgano/métodos , Enfermedad de Parkinson/tratamiento farmacológico , Animales , Quimioterapia Adyuvante , Bases de Datos Bibliográficas/estadística & datos numéricos , Humanos , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
The objective of this meta-analysis was to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression in patients with Parkinson disease in order to arrive at qualitative and quantitative conclusions about the efficacy of rTMS. We included randomized controlled trials examining the effects of rTMS compared with sham-rTMS or selective serotonin re-uptake inhibitors (SSRIs). The quality of included studies was strictly evaluated. Data analyses were performed using the RevMan5.1 software. Eight studies including 312 patients met all inclusion criteria. The results showed that rTMS could evidently improve the HRSD score compared with sham-rTMS (p < 0.00001). However, we found similar antidepressant efficacy between rTMS and SSRIs groups in terms of HRSD and BDI score (p = 0.65; p = 0.75, respectively). Furthermore, patients who received rTMS could evidently show improvement on the unified Parkinson's disease rating scale (UPDRS), ADL score, and UPDRS motor score compared with sham-rTMS or SSRIs (p < 0.05, p = 0.05, respectively). The subgroup analysis by frequency of rTMS evidenced that the efficacy of low-frequency rTMS was superior to sham-rTMS (p < 0.0001) in terms of the outcome measure according to HAMD scale. Meanwhile, the high-frequency rTMS has the same antidepressant efficacy as SSRIs (p = 0.94). The current meta-analysis provided evidence that rTMS was superior to sham-rTMS and had similar antidepressant efficacy as SSRIs, and may have the additional advantage of some improvement in motor function.
Asunto(s)
Trastorno Depresivo/terapia , Enfermedad de Parkinson/terapia , Estimulación Magnética Transcraneal , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Estimulación Magnética Transcraneal/métodosRESUMEN
Design of advanced carbon nanomaterials with high-efficiency oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) activities is still imperative yet challenging for searching green and renewable energies. Herein, we synthesized ultrafine FeNi/(FeNi)9S8 nanoclusters encapsulated in nitrogen, sulfur-codoped graphitic carbon nanosheets (FeNi/(FeNi)9S8/N,S-CNS) by coordination regulated pyrolyzing the mixture of the metal precursors, dithizone and g-C3N4 at 800 °C. The as-prepared FeNi/(FeNi)9S8/N,S-CNS exhibited distinct electrocatalytic activity and stability for the ORR with positive onset (Eonset) and half-wave (E1/2) potentials (Eonset = 0.97 V; E1/2 = 0.86 V) and OER with the small overpotential (η = 283 mV) at 10 mA cm-2 in the alkaline media, outperforming commercial Pt/C and RuO2 catalysts. This research provides some constructive guidelines for preparing efficient, low-cost and stable nanocatalysts for electrochemical energy devices.
RESUMEN
It is imperative to design and manufacture electrocatalysts towards oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) for popularization of rechargeable Zn-air batteries. Herein, FeNi alloy confined in N-doped carbon nanosheets (FeNi@NCSs) was harvested via a facile complexation-pyrolysis strategy from the mixture of guanine and metal chlorides. After strictly exploring the pyrolysis temperature and metal types, the resulted FeNi@NCSs showed greatly improved performances on both the ORR (onset potential of 0.93 V and half-wave potential of 0.84 V) and OER (overpotential of 318 mV at 10 mA cm-2 and 379 mV at 100 mA cm-2). Further, the FeNi@NCSs based Zn-air battery exhibited a higher open circuit voltage (1.496 V), a larger power density (128.8 mW cm-2), and prominent durability (360 cycles, 120 h). This study provides an appealing approach to utilize biomass for synthesis of low-cost and high-efficiency electrocatalysts in energy associated systems.
Asunto(s)
Carbono , Cinostatina , Aleaciones , Cloruros , Electrodos , Guanina , Oxígeno , ZincRESUMEN
Currently, it is critical but a tricky point to develop economical, high-efficiency, and durable non-precious metal electrocatalysts towards oxygen reduction and oxygen evolution reaction (ORR/OER) in rechargeable Zn-air batteries. Herein, N, Mn-codoped three-dimensional (3D) fluffy porous carbon nanostructures encapsulating FeCo/FeCoP alloyed nanoparticles (FeCo/FeCoP@NMn-CNS) are prepared by one-step pyrolysis of the metal precursors and polyinosinic acid. The optimized hybrid nanocomposite (obtained at 800 °C, named as FeCo/FeCoP@NMn-CNS-800) exhibits outstanding catalytic performance in the alkaline electrolyte with a half-wave potential (E1/2) of 0.84 V for the ORR and an overpotential of 325 mV towards the OER at 10 mA cm-2. Impressively, the FeCo/FeCoP@NMn-CNS-800-assembled rechargeable Zn-air battery presents an open-circuit voltage of 1.522 V (vs. RHE), a peak power density of 135.0 mW cm-2, and long-term durability by charge-discharge cycling for 200 h, surpassing commercial Pt/C + RuO2 based counterpart. This work affords valuable guidelines for exploring advanced bifunctional ORR and OER catalysts in rational construction of high-quality Zn-air batteries.
RESUMEN
For development of green and sustainable energy, it is of importance to search highly efficient and low-cost electrocatalysts of oxygen reduction reaction (ORR) in energy conversion devices. Herein, CoFe alloyed nanocrystals embedded in N-doped bamboo-like carbon nanotubes (CoFe@NCNTs) were facilely synthetized by one-step co-pyrolysis with the mixture of triamterene, metal chlorides and graphitic carbon nitride (g-C3N4). The resultant CoFe@NCNTs exhibited excellent ORR activity with the positive shifts in the onset potential (Eonset = 0.97 V) and half-wave potential (E1/2 = 0.88 V), outperforming commercial Pt/C (Eonset = 0.96 V; E1/2 = 0.84 V). Compared to metal organic frameworks (MOFs)-based strategy for synthesis of low-cost carbon-based ORR catalysts, this method is simple and convenient, coupled by avoiding the complicated synthesis of MOFs and its ligands. This work provides a promising route to fabricate advanced transition-metal-based carbon catalysts in the researches correlated with energy conversion devices.
RESUMEN
The traditional Chinese medicine of Qingxin Kaiqiao Recipe (QKR) is effective in the treatment of Alzheimer's disease (AD). This study aims to investigate whether QKR improves the cognitive ability and takes neuroprotective effect on APP/PS1 double transgenic mice via the PI3K/Akt pathway. APP/PS1 double transgenic mice were randomly divided into a model, donepezil-treated, or QKR-treated group (L-QKR: 4.75 mg/kg/d, M-QKR: 9.5 mg/kg/d, and H-QKR: 19 mg/kg/d, respectively). Wild-type C57/BL6J mice were used as the control group. Morris water maze (MWM) was used to test the ability of spatial navigation and memorization; terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling (TUNEL) assay was applied to test the apoptosis; amyloid protein granule deposition was detected via Methenamine silver staining; Western blot (WB) analysis, immunohistochemistry, and RT-PCR were applied to measure the expression of Aß and corresponding indicators of the PI3K/Akt pathway. Compared with the model group, QKR significantly relieved the cognitive impairment, reduced the deposition of senile plaques, decreased the expression of GSK-3α and Aß, and increased the expression of p-PI3K, p-Akt, and IDE. In addition, the number of TUNEL-positive cells decreased after treatment using QKR. The current study proved that QKR, especially at the high dose tested, exerted a protective effect on improving learning and memory, inhibiting apoptosis, and reducing the process of pathological degeneration in the hippocampus of AD mice.
RESUMEN
Deep brain stimulation (DBS) is the surgical procedure of choice for patients with advanced Parkinson disease (PD). We aim to evaluate the efficacy of GPi (globus pallidus internus), STN (subthalamic nucleus)-DBS and medical therapy for PD. We conducted a systematic review and multiple-treatments meta-analysis to investigate the efficacy of neurostimulation and medical therapy for PD patients. Sixteen eligible studies were included in this analysis. We pooled the whole data and found obvious difference between GPi-DBS versus medical therapy and STN-DBS versus medical therapy in terms of UPDRS scores (Unified Parkinson's Disease Rating Scale). Meanwhile, we found GPi-DBS had the similar efficacy on the UPDRS scores when compared with STN-DBS. What is more, quality of life, measured by PDQ-39 (Parkinson's disease Questionnaire) showed greater improvement after GPi-DBS than STN-DBS. Five studies showed STN-DBS was more effective for reduction in medication than GPi-DBS. Overall, either GPi-DBS or STN-DBS was an effective technique to control PD patients' symptoms and improved their functionality and quality of life. Meanwhile, the UPDRS scores measuring parkinsonian symptoms revealed no significant difference between GPi-DBS and STN-DBS. STN-DBS was more effective for reduction in medication than GPi-DBS. Alternatively, GPi-DBS was more effective for improving the PDQ-39 score than STN-DBS.